Multidrug resistant anticancer anthracyclines
US7737123B2 · kind B2 · utility
0Cited by
3References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 12, 2006 |
| Grant date | Jun 15, 2010 |
| Priority date | — |
| Expiry date | Jul 13, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/056
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Daunorubicin (“DNR”) compounds synthesized with uncommon sugars exhibit enhanced effectiveness in treating various drug-resistant cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.